DOLPAC 10 VETERINARY

국가: 이스라엘

언어: 영어

출처: Ministry of Health

유효 성분:

OXANTEL AS EMBONATE; PRAZIQUANTEL; PYRANTEL EMBONATE

제공처:

ELIEZER LINEVITZ LTD.

약제 형태:

TABLETS

구성:

OXANTEL AS EMBONATE 200.28 MG; PYRANTEL EMBONATE 49.94 MG; PRAZIQUANTEL 50 MG

관리 경로:

PER OS

처방전 유형:

Required

Manufactured by:

VETOQUINOL S.A., FRANCE

치료 징후:

For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages of nematodes and cestode species : Nemtodes : toxocara canis toxocaris leonine ancylostoma caninum uncinaria stenocephala trichuris vulpis. Cestodes : Dipylidum caninum taenia spp.

승인 날짜:

2020-08-31

환자 정보 전단

VETERINARY MEDICINE PACKAGE LEAFLET
This medicine is dispensed with a veterinarian’s prescription only
For use in animals only
DOLPAC 10 VETERINARY - oral tablets for dogs
DOLPAC 25 VETERINARY - oral tablets for dogs
COMPOSITION:
ACTIVE INGREDIENTS:
DOLPAC 10 VETERINARY:
DOLPAC 25 VETERINARY:
200.28 mg of oxantel (as embonate)
49.94 mg of pyrantel (as embonate)
50.00 mg of praziquantel
500.70 mg of oxantel (as embonate)
124.85 mg of pyrantel (as embonate)
125.00 mg of praziquantel
INACTIVE INGREDIENTS:
dextrates, povidone K30, lauryl sodium sulphate, bacon flavor,
crospovidone,
sodium stearyl fumarate.
INDICATION:
Treatment of parasitic infestation with adult stages of roundworms and
tapeworms in dogs
NEMATODES AND CESTODES:
NEMATODES: Toxocara canis, Toxascaris leonina, Ancylostoma caninum,
Uncinaria stenocephala, Trichuris vulpis.
CESTODES: Dipylidium caninum, Taenia spp_._
SIDE EFFECTS:
Vomiting and diarrhea may appear in the dog during the course of
treatment.
Anorexia is a common side effect of praziquantel; however, it was not
observed in studies of Dolpac. If you notice any serious side effect
not
mentioned in this leaflet, tell your veterinarian.
You can report side effects to the Ministry of Health by following the
link
‘Reporting Side Effects of Drug Treatment’ on the Ministry of
Health home
page (www.health.gov.il) which links to an online form for reporting
side
effects. You can also use this link:
https://sideeffects.health.gov.il
DOSAGE AND DIRECTIONS FOR USE:
Dosage table:
DOLPAC 10
The recommended dose is 20
mg oxantel / 5 mg pyrantel / 5
mg praziquantel per kg
bodyweight, which is one tablet
DOG WEIGHT
NUMBER OF TABLETS
3.1-5 kg
5.1-10 kg
10.1-20 kg
20.1-30 kg
½
1
2
3
per 10 kg bodyweight. For oral
administration.
DOLPAC 25
The recommended dose is 20
mg oxantel / 5 mg pyrantel / 5
mg praziquantel per kg
bodyweight, which is one tablet
per 25 kg bodyweight. For oral
administration.
DOG WEIGHT
NUMBER OF TABLETS
10.1-12.5 kg
12.6-25 kg
25.1-50 kg
50.1-75 kg
½
1
2
3
Administer the required nu

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
DOLPAC 10 VETERINARY
DOLPAC 25 VETERINARY
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
DOLPAC 10 VETERINARY:
Oxantel
…………………………………………………...(as
embonate)
(equivalent to 559 mg of oxantel embonate)
200.28 mg
Pyrantel…………………………………………………...(as
embonate)
(equivalent to 144 mg of oxantel embonate)
49.94 mg
Praziquantel ……………………………………………..
50.00 mg
Excipient QS for one pre-scored 950-mg tablet
For the full list of excipients, see ‘List of excipients’ section.
DOLPAC 25 VETERINARY:
Oxantel
…………………………………………………...(as
embonate)
(equivalent to 1395,5 mg of oxantel embonate) 500.70 mg
Pyrantel…………………………………………………...(as
embonate)
(equivalent to 360 mg of oxantel embonate)
124.85 mg
Praziquantel ……………………………………………..
125.00 mg
Excipient QS for one pre-scored 2375-mg tablet
For the full list of excipients, see ‘List of excipients’ section.
3. PHARMACEUTICAL FORM
Tablet.
Pale yellow to yellow oblong tablet with breaking line.
4. CLINICAL PARTICULARS
4.1. TARGET SPECIES
Dogs.
4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For curative treatment of dogs harbouring mixed parasitic infestations
with the following adult
stages of nematodes and cestode species :
Nemtodes :
toxocara canis, toxocaris leonine, ancylostoma caninum, uncinaria
stenocephala, trichuris vulpis.
Cestodes :
Dipylidum caninum taenia spp.
4.3. CONTRAINDICATIONS
See ‘Interaction with other medicinal products and other forms of
interactions’ section.
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
4.4. SPECIAL WARNINGS FOR EACH TARGET SPECIES
Parasite resistance to any particular class of anthelmintic may
develop following frequent and
repeated use of an anthelmintic from that class.
As fleas serve as intermediate